Cosmo
Manufacturing · Ireland · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Riverside Ii Sir John Rogerson's Quay, D...Phone Number
+353 18170370Website
www.cosmopharma.comRevenue
$212 MillionStock Symbol
COPNIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Cosmo
Cosmo Pharmaceuticals NV is a pharmaceutical company focused on becoming a leader in gastroenterology and dermatology. The company has developed a proprietary clinical pipeline targeting innovative treatments for gastrointestinal diseases and skin conditions, addressing unmet medical needs. With six approved drugs and two medical devices, Cosmo licenses its products to partners with strong marketing capabilities. Its mission includes providing improved healthcare solutions while engaging in sustainable practices.Explore more
Cosmo Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cosmo your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Cosmo has new funding data
Earning: See what the market has to say on Cosmo recently announced quarterly report
Check if Cosmo has recently received funding, and reach out quickly before it becomes old news!
Check out if Cosmo is spiking on competitors!
Click to see if Cosmo had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Cosmo, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Cosmo launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Cosmo
Recommended Actions
Find VP level buyers at Cosmo
Find 3 more new buyers
Company Profile Activity
Activity Insights
Cosmo is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cosmo is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cosmo.
Cosmo Tech Stack
A closer look at the technologies used by Cosmo
Most Recent Scoops
Earnings
Cosmo has reported approximately breakeven EBITDA for H1 FY2026, with cost of sales increasing 9% broadly in line with commercial and CDMO growth, R&D expenses declining 16% following the completion of Phase III clascoterone studies, and SG&A expenses increasing year-over-year due to non-cash amortization from the European Winlevi launch and prior-period capability investments. Operating expenses are expected to decline modestly in H2 compared to H1.
Earnings, Research & Development, Finance
Project
Cosmo has announced that enrollment for its distal ulcerative colitis Phase II program has been accelerated and completed, with a Phase II publication expected by year-end, while enrollment for the bile acid diarrhea Phase II program remains on track to close by year-end. Decisions on partnering, licensing, or advancing either program to Phase III will be reassessed as milestones are reached.
Pharmaceuticals, Clinical Operations
Project
Cosmo has announced that Phase II enrollment for its candidate colesevelam MMX, a colon-targeted therapy for bile acid diarrhea, is completing toward year-end, targeting an addressable market of approximately EUR 21 billion across an estimated 95 million patients worldwide with no currently dedicated therapy.
Clinical Operations
Earnings
Cosmo has reaffirmed full-year FY2026 guidance, expecting total revenues of EUR 105 to 110 million, including EUR 98 to 102 million in recurring revenues and EUR 7 to 8 million in project-based revenues, with H2 revenues expected to accelerate versus H1. Cosmo also continues to expect EBITDA of EUR 10.5 to 13.5 million, representing double-digit year-over-year growth, and anticipates ending the year with approximately EUR 200 million in cash equivalents and short-term investments while remaining debt-free.
Earnings, Finance
Project
Medical Research, Pharmaceuticals
Cosmo News & Media
Phase 3 Data Support a Novel Mechanism for Male Hair Loss: Spokane Dermatologist Dr. Wm. Philip Werschler on the Significance of the Clascoterone Results
New 12-month results reported by Cosmo Pharmaceuticals for an investigational topical solution suggest a possible new approach in androgenetic alopecia. A veteran dermatologist and clinical trial investigator weighs in on the science and the unmet need. New 12-month results reported by Cosmo Pharmaceuticals for an investigational topical solution suggest a possible new approach in androgenetic alopecia. A veteran dermatologist and clinical trial investigator weighs in on the science and the unmeCosmo and Glenmark Announce Market Authorisation of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 17 countries in Europe
DUBLIN and MUMBAI, India, Dec. 1, 2025 /PRNewswire/ -- Cosmo Pharmaceuticals N.V. (SIX: COPN) ("Cosmo") and Glenmark Pharmaceuticals Limited (Glenmark), announced that the European Commission (EC) has granted Marketing Authorization (MA) for Winlevi® (clascoterone 10 mg/g cream),...Cosmo Pharmaceuticals (SWX:COPN): Assessing Valuation Following Recent Share Price Momentum
Shares of Cosmo Pharmaceuticals (SWX:COPN) have drawn interest lately as investors take a closer look at its recent performance. Over the past month, the stock is down 2%, but it remains up 17% for the past 3 months. See our latest analysis for Cosmo Pharmaceuticals. Looking at the bigger picture, Cosmo Pharmaceuticals’ share price return shows clear momentum. A hefty 17.3% gain over the last 90 days stands out against a modest 6% total shareholderCosmo Pharmaceuticals And Two More Top Dividend Stocks To Consider
In a week marked by cautious Federal Reserve commentary and looming political uncertainties, global markets experienced notable fluctuations, with U.S. stocks facing broad-based declines despite a late-week rally. As investors navigate these turbulent waters, dividend stocks often appeal for their potential to provide steady income streams amidst market volatility. When considering what makes a good dividend stock in such an environment, it's crucial to look for companies with strong...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cosmo
Sign Up For FreeTo access detailed company insights
Cosmo Pharmaceuticals NV is a pharmaceutical company focused on becoming a leader in gastroenterology and dermatology. The company has developed a proprietary clinical pipeline targeting innovative treatments for gastrointestinal diseases and skin conditions, addressing unmet medical needs. With six approved drugs and two medical devices, Cosmo lic... Read More
